Showing results (361-370 of 378) with videos related to

Sort By:
Pageof 38
Journal of Internal Medicine|February 7, 2019
Prevention, monitoring and treatment of cardiovascular adverse events in myeloma patients receiving carfilzomib A consensus paper by the European Myeloma Network and the Italian Society of Arterial HypertensionS Bringhen, A Milan, M D'Agostino, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 16, 2004
Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology GroupG Fountzilas, H P Kalofonos, U Dafni, et al.
Leukemia|December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVORW-J Chng, H Goldschmidt, M A Dimopoulos, et al.
Leukemia|March 19, 2014
Preserved levels of uninvolved immunoglobulins are independently associated with favorable outcome in patients with symptomatic multiple myelomaE Kastritis, F Zagouri, A Symeonidis, et al.
Leukemia|August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR studyP Moreau, D Joshua, W-J Chng, et al.
Leukemia|November 2, 2013
International Myeloma Working Group recommendations for global myeloma careH Ludwig, J S Miguel, M A Dimopoulos, et al.
Leukemia|July 21, 2006
International uniform response criteria for multiple myelomaB G M Durie, J-L Harousseau, J S Miguel, et al.
Seminars in Hematology|May 5, 2023
Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patientsS D'Sa, J V Matous, R Advani, et al.
Seminars in Hematology|April 26, 2023
Report of consensus panel 7 from the 11th international workshop on Waldenström macroglobulinemia on priorities for novel clinical trialsC S Tam, P Kapoor, J J Castillo, et al.
Leukemia|July 16, 2016
A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)R Hájek, T Masszi, M T Petrucci, et al.
Pageof 38